Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vale SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Vale SA trades at $14.24 (market cap $60.94B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays a 8.7% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VALE | |
|---|---|---|
Market Cap | $39.89B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $17.82 |
52-Week Low | $278.09 | $9.53 |
Enterprise Value | $38.15B | $77.86B |
Dividend Yield | — | 8.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VALE trades at $14.46, up 1.69% with mixed earnings performance including a Q3 2025 beat but recent misses. Technical indicators show bearish momentum with oversold RSI signals. The company maintains solid cash flow generation ($2.42B net in 2025) despite declining profit margins from 42.85% in 2022 to 6.12% in 2025. Recent news highlights $2.56B decarbonization investments and governance developments.
VALE presents a cautious opportunity with analyst consensus at $17.50 (21% upside) but faces margin compression and debt increases. The stock's value proposition hinges on commodity price recovery and successful execution of efficiency initiatives amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
